Λογότυπο www.galinos.gr Beta
 

Ιατροφαρμακευτική πληροφόρηση για τον επαγγελματία υγείας

Φάρμακα Δραστικές ουσίες Συμπληρώματα διατροφής Έλεγχος συγχορήγησης Νόσοι ICD-10
Κλαύδιος Γαληνός
Είσοδος χρηστών
Όνομα χρήστη
Συνθηματικό
Εικονίδιο Είσοδος χρήστη
Εικονίδιο Δωρεάν εγγραφή
Εικονίδιο Ανανέωση συνθηματικού

Ακολουθήστε μας Λογότυπο Facebook Λογότυπο Twitter

Αναζήτηση σε 63811 καταχωρήσεις
Εικονίδιο αναζήτησης

Βιβλιογραφική αναφορά

Προτάσεις

SPC, UK: ECALTA 100 mg powder for concentrate for solution for infusion (2012)

Εκδότης

Εκδότης Pfizer Limited
Διεύθυνση Ramsgate Road, Sandwich, Kent, CT13 9NJ
Σφάλμα Για την προβολή της πλήρους καταχώρησης χρειάζεται να έχετε συνδρομή σε ισχύ (αγορά συνδρομής).
Ολοκληρώνοντας τη διαδικασία δωρεάν εγγραφής θα αποκτήσετε, χωρίς καμία δέσμευση εκ μέρους σας, συνδρομή διάρκειας 30 ημερών.

Περιεχόμενα

Name of the medicinal product

ECALTA ® 100 mg powder for concentrate for solution for infusion.

Qualitative and quantitative composition

Each vial contains 100 mg anidulafungin. The reconstituted solution contains 3.33 mg/ml anidulafungin ...

Pharmaceutical form

Powder for concentrate for solution for infusion. White to off-white lyophilised solid. The reconstituted ...

Therapeutic indications

Treatment of invasive candidiasis in adult non-neutropenic patients. ECALTA has been studied primarily ...

Posology and method of administration

Treatment with ECALTA should be initiated by a physician experienced in the management of invasive fungal ...

Contraindications

Hypersensitivity to the active substance, or to any of the excipients listed in section 6.1. Hypersensitivity ...

Special warnings and precautions for use

The efficacy of ECALTA in neutropenic patients with candidaemia and in patients with deep tissue Candida ...

Interaction with other medicinal products and other forms of interaction

Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes ...

Fertility, pregnancy and lactation

Pregnancy There are no data regarding the use of anidulafungin in pregnant women. Slight developmental ...

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

Undesirable effects

Summary of the safety profile Nine hundred and twenty-nine (929) subjects received single or multiple ...

Overdose

As with any overdose, general supportive measures should be utilised as necessary. In case of overdose, ...

Pharmacodynamic properties

Pharmacotherapeutic group: Antimycotics for systemic use, other antimycotics for systemic use ATC code: ...

Pharmacokinetic properties

General pharmacokinetic characteristics The pharmacokinetics of anidulafungin have been characterised ...

Preclinical safety data

In 3 month studies, evidence of liver toxicity, including elevated enzymes and morphologic alterations, ...

List of excipients

Fructose Mannitol Polysorbate 80 Tartaric acid Sodium hydroxide (for pH-adjustment) Hydrochloric acid ...

Incompatibilities

This medicinal product must not be mixed with other medicinal products or electrolytes except those mentioned ...

Shelf life

3 years Excursions for 96 hours up to 25°C are permitted, and the powder can be returned to refrigerated ...

Special precautions for storage

Store in a refrigerator (2°C – 8°C). For storage conditions after reconstitution and dilution of the ...

Nature and contents of container

30 ml Type 1 glass vial with an elastomeric stopper (butyl rubber with an inert polymer coating on the ...

Special precautions for disposal and other handling

There are no special requirements for disposal. ECALTA must be reconstituted with water for injections ...

Marketing authorization holder

Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom

Marketing authorization number(s)

EU/1/07/416/002

Date of first authorization / renewal of the authorization

Date of first authorisation: 20 September 2007 Date of latest renewal: 23 August 2012

Date of revision of the text

August 2012
Απαγορεύεται η αναπαραγωγή και αναδιανομή. Το έργο επεξεργασίας των παραπάνω πληροφοριών αποτελεί πνευματική ιδιοκτησία της Ergobyte Πληροφορική Α.Ε. και προστατεύεται από τη νομοθεσία περί πνευματικών δικαιωμάτων.